To review the drugs used in the treatment of chronic venous diseases of the lower limb.
Data sources:
Published papers referring to the pharmacology of drugs used in the management of chronic venous insufficiency and varicose veins of the lower limb.
Study selection:
Sixty-four papers referring to the use of horse chestnut extract (aescin), flavonoids, tribnoside and calcium dobesilate have been included.
Data extraction:
Papers were examined to establish the mechanism of action of ‘oedema protective’ drugs.
Data synthesis:
Oedema protective drugs modify the permeability of the microcirculatory endothelium in animal models of oedema and probably in patients with venous disease to reduce transcapillary loss of fluid into the tissues. The exact mechanisms of action remain unclear.
Conclusion:
Animal and clinical studies demonstrate that drugs of the four types included in this review moderate the development of tissue oedema.
RegenthalRVoigtHGroßmannK. Möglichkeiten and Grenzen der Pharmakotherapie der chronisch-venösen Insuffizienz. Z Ges Inn Med1990; 45: 108–12.
6.
LorenzDMarekML. Das therapeutisch wirksame Prinzip der Roßkastanie (Aesculus hippocastanum). Arzneim-Forsch/Drug Res1960; 10: 263–72.
7.
HampelHHofrichterGLeihnH-DSchlemmerW. Zur Pharmakologie der Aescin-Isomere unter besonderer Berüksichtigung von Aescin. Arzneim-Forsch/Drug Res1970; 20: 209–28.
8.
RothkopfMVogelG. Neue Befunde zur Wirksamkeit und zum Wirkungsmechanismus des Roßkastaniensaponins Aescin. Arzneim-Forsch/Drug Res1976; 26: 225–35.
9.
HitzenbergerG. Die therapeutische Wirksamkeit des Roßkastaniensamenextraktes. Wien Med Wochenschr1989; 139: 385–9.
WadworthANFauldsD. Hydroxyethylrutosides. A review of its pharmacology and therapeutic efficacy in venous insufficiency and related disorders. Drugs1992; 44: 1013–32.
12.
CanestriE AltmannLeguizamonOGSanchezCCuccareseMMartinG. Calcium dobesilate (Doxium) in the treatment of venous insufficiency. A pharmacological and clinical study. In: Proceedings of the Sixth World Congress of Phlebology, Buenos Aires, Argentina, 1977.
13.
JaquesR. Charakterisierung der pharmakologischen Wirkungsweise von Glyvenol. In: KappenA, Editor. Chronisch venöse Insuffizienz – Neue Aspekte. Basel: Ciba-Geigy, 1971: 120–7.
EisenburgerRHofrichterGLiehnH-DLudwigE. Zur Pharmakodynamik von alpha- und beta-Aescin nach Applikation per os. Arzneim-Forsch/Drug Res1976; 26: 821–4.
16.
VogelGStröckerH. Die Wirkung von Pharmaka – insbesondere von Flavonoiden und Aescin – auf den Lymphfluß und die Permeabilität der kintakten Plasma-Lymph-Schranke von Ratten für Flüssigkeit und definierte Makromoleküle. Arzneim-Forsch/Drug Res1966; 16: 1630–4.
17.
BörscökEFöldiKGyöriIÖtZFöldiM. Treatment of experimental lymphoedema with the semi-synthetic bioflavonoid O-(β-hydroxyethyl)-rutosides (HR). Angiologica1970; 7: 51–2.
18.
GerdinBSvensjöE. Inhibitory effect of the flavonoid O-(β-hydroxyethyl)-rutosides on increased microvascular permeability induced by various agents in rat skin. Int J Microcirc1983; 2: 39–46.
19.
BlumbergSCloughGMichelC. Effects of hydroxyethyl rutosides upon the permeability of single capillaries in the frog mesentery. Br J Pharm1989; 96: 913–9.
20.
FelixW. Zur Wirkung von O-(β-Hydroxyethyl)-rutosiden auf die Ödembildung durch Ethoxysklerol und Thiopental am Hinterlauf der Katze. In: VoelterWJungG, Editors. O-(β-Hydroxyethyl)-rutoside – experimentelle und klinische Ergebnisse. Berlin-Heidelberg-New York: Springer Verlag, 1978: 93–102.
21.
NeesS. Protektive Wirkung von O-(β-Hydroxyethyl)-rutosiden auf das myokardiale Mirkrogefäßsystem In: Betahydroxyethyl-rutoside, Medikon-Verlag, 1992.
22.
LabridCPerdrixL. Mechanisms of oedema: Activity of Daflon 500 mg. Phelebology1992; 7 (suppl 2): 30–6.
23.
GaborMEngiESonkodiS. Die Kapillarwandresistenz und hire Beeinflussung durch wasserlösliche Flavon-derivate bei spontan hypertonen Ratten. Phlebologie1993; 22: 178–82.
24.
VijayaraghavanRSugendranKPantSCHusainKMalhotraRC. Dermal intoxication of mice with bis(2-chloroethyl)sulphide and the protective effect of flavonoids. Toxicology1991; 69: 35–42.
25.
DamonMFlandreOMichelFPerdrixLLabridCde PauletA Crastes. Effect of chronic treatment with a purified flavonoid fraction on inflammatory granuloma in the rat. A study of prostaglandin E2 und F2α and thromboxane B2 release and histological changes. Arzneim-Forsch/Drug Res1987; 37: 1149–53.
26.
LerondL. Action of Daflon 500 mg on the principal inflammatory mediators. Phlebology1994; 9 (suppl 1): 34–9.
27.
GodfraindT. Effect of a flavonoid preparation (S 5682) on experimental capillary permeability increase in rat paw and rabbit skin. Int Angiol1988; 7: 17–9.
28.
SinzingerHRauschaFVinazzerH. Platelet function and prostaglandins in patients with peripheral vascular disease treated with calcium dobesilate. Prostaglandins, Leukotrienes and Medicine1987;29: 1–9.
29.
SvensjöEArforsKEArtursonG. Effect of inhibition of PGE2-Activity on FITC-dextran permeability in the hamster microvasculature. Bibliotheca Anatomica1974; 13: 303–4.
30.
EnghoferESeibelKHammersenF. Die antiexsudative Wirkung von Roßkastaniensamenextrakt. Neue Ergenbnisse zu ihrem Mechanismus. Therapiewoche1984; 34: 4130–44.
31.
BeharALagrueGCohen-BoulakiaFBailletJ. Study of capillary filtration by double labelling I131 albumin and Tc99m red cells. Application to the pharmacodynamic activity of Daflon 500 mg. Int Angiol1988; 7: 35–8.
RoztocilKOlivaI Prerovsky. The effect of hydroxyethylrutosides on capillary filtration rate in the lower limb of man. Eur J Clin Pharmacol1977; 11: 435–8.
34.
BislerHPfeiferRKlükenNPauschingerP, Wirkung von Roßkastaniensamenextrakt auf die transkapilläre Filtration bei chronischer venöser Insuffizienz. Dtsch Med Wochenschr1986; 111: 1321–9.
35.
BelcaroGD'AulerioARuloACandianiC. Evaluation of capillary permeability and microcirculation in patients with chronic venous hypertension treated with Venoruton by the vacuum suction chamber device and laser-Doppler flowmetry. Phlebologie1988; 41: 847–56.
36.
McHaleNGHollywoodMA. Control of lymphatic pumping: Interest of Daflon 500 mg. Phlebology1994; 9 (suppl 1): 23–5.
37.
CotonatACotonatJ. Lymphagogue and pulsatile activities of Daflon 500 mg on canine thoracic lymph duct. Int Angiol1989; 8 (suppl 4): 15–8.
38.
NiebesPLasztL. Influence in vitro d'une serie de flavonoides sur des enzymes du metabolisme des mucopolysaccharides de veines saphenes humaines et bovinesAngiologica1971: 297–302.
39.
KreyselHWNissenHPEnghoferE. A possible role of lysosomal enzymes in the pathogenesis of varicosis and the reduction in their serum activity by Venostasin. VASA1983; 12: 377–82.
40.
van CaneghemP. Influence of some hydrosoluble substances with vitamin D activity on the fragility of lysosomes in vitro. Biochem Pharmacol1972; 21: 1543–8.
41.
RaoCNRaoVHVerbruggenLOrloffS. Effect of bioflavonoids on lysosomal acid hydrolases and lysosomal stability in adjuvant-induced arthritis. Scand J Rheumatol1980; 9: 280–4.
42.
FalkayGKovacsL. Calcium dobesilate (Doxium) as a prostaglandin synthetase inhibitor in pregnant myometrium in vitro. Experientia1984; 40: 190.
43.
ShuklaVKSethiAKGargSKGangulyNKKulkarniSK. Effect of Venoruton on hypoxic stress-induced neurotoxicity in mice and oxygen free radical generation by human neutrophils. Arch Int Pharmacodyn1989; 299: 127–33.
44.
CyprianiBLimassetBCarriéMLLe DoucenCRoussieMde PauletA CrastesDamonM. Antioxidant activity of micronized diosmin on oxygen species from stimulated human neutrophils. Biochem Pharmacol1993; 45: 1531–5.
45.
FrieseneckerBTsaiAGAllegraCAntagliettaM. Oral administration of purified micronized flavonoid fraction suppresses leucocyte adhesion in ischemia-reperfusion injury: In vivo observations in the hamster skinfold. Int J Microcirc1994; 14: 50–5.
46.
RekkaIKourounakisPN. Effect of hydroxyethyl rutosides and related compounds on lipid peroxidation and free radical scavenging activity. Some structural aspects. J Pharm Pharmacol1991; 43: 486–91.
47.
HammersenF. The ultrastructural changes in the microcirculation in experimental edema: A suitable morphological test-model for the effect of vasoactive drugs. Biorheololgy1970; 6: 343–6.
48.
PreziosiPMancaP. Die Antiödem- und die antiinflammatorische Wirkung von Aescin und ihre Beziehung zur Hypophysen-Nebennieren-Achse. Arzneim-Forsch/Drug Res1965; 15: 404–13.
49.
HammersenF. Ein morphologischer Beitrag zum Wirkungsmechanismus gefäßaktiver Pharmaka. Fortschr Med1972; 90: 609.
50.
ThielHJHammersenFSauerR. Histochemische und ultrastrukturelle Untersuchungen zur antiödematösen und radioprotektiven Wirkung von O-(β-Hydroxyethyl)-rutosiden am Rattenhirn nach Einzeitbestrahlung. Stranhlentherapie und Onkologie1988; 164: 544–52.
51.
HenschlerDHempelKSchultzeBMaurerW. Zur Pharmakokinetik von Aescin. Arzneim-Forsch/Drug Res1971; 21: 1682.
52.
LangWMennickeWH. Pharmakokinetische Untersuchungen mit tritiiertem Aescin an Maus und Ratte. Arzneim-Forsch/Drug Res1972; 22: 1928–32.
53.
NeumannHACarlsonKBromGH. The uptake and localization of O-(β-hyroxyethyl)-rutosides in the venous wall, measured by laser scanning microscopy. Eur J Clin Pharm1992; 26: 20–7.
54.
BenakisA. Métabolisme et pharmacocinétique du dobésilate de calcium. Thérapie1974; 29: 211.
55.
PauschingerPWörzEZwergerE. Die Messung des Filtrationskoeffizienten am menschlichen Unterschenkel und seine pharmakologische Beeinflussung. Med Welt1981; 32: 1954–6.
56.
HachenHJLorenzP. Double-blind clinical and Plethysmographic study of calcium dobesilate in patients with peripheral microvascular disorders. Angiology1982; 33: 480–8.
57.
RudofskyGNeißAOttoKSeibelK. Ödemprotektive Wirkung und klinische Wirksamkeit von Roßkastanien-samenextrakt im Doppelblindversuch. Phlebol Proktol1986; 15: 47–54.
58.
VinazzerHHachenHJ. Influence of calcium dobesilate (Doxium) on blood viscosity and coagulation parameters in diabetic retinopathy. VASA1987; 16: 190–2.
59.
KöltringerPEberORothlauerWKlimaGLindPLangstegerWWakonigP. Calcium dobersilate and its effects on hemorheology and microcirculation. Int J Clin Pharmacol Ther Toxicol1988; 26: 500–2.
60.
AndroulakisGPanoysisPA. Plethysmographic confirmation of the beneficial effect of calcium dobesilate in primary varicose veins. Angiology1989; 40: 1–4.
61.
CesaroneMRLauroraGRicciABelcaroGPomantePCandianiCLeonMNicolaidesAN. Acute effects of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose comparison study). VASA1992; 21: 76–80.
62.
GalleyPThiolletM. A double blind, placebo controlled trial of a new venoactive flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility. Int Angiol1993; 12: 69–72.
63.
BarbeRAmielM. Pharmacodynamic properties and therapeutic efficacy of Daflon 500 mg. Phlebology1994; 9 (suppl 1): 41–4.
64.
GuillotB. Techniques used to evaluate the cutaneous microcirculation: Application of photoplethysmography to the assessment of phlebotropic agent in the treatment of leg ulcers. Angiology1994; 45 (suppl): 542–8.
